Last updated: October 20, 2023
Sponsor: Assiut University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Diabetes And Hypertension
Diabetes Prevention
Treatment
Pembrolizumab
Clinical Study ID
NCT06100796
ICI outcomes in NSCLC with DM
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- All consecutive patients with advanced Non Small Cell Lung Cancer who received ImmuneCheck Inhibitors alone or in combination with chemotherapy, either as first line or asa subsequent line
Exclusion
Exclusion Criteria:
- None
Study Design
Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Pembrolizumab
Phase:
Study Start date:
October 01, 2023
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Assiut university
Assiut, 71515
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.